The latest quarterly earnings report for Bausch Health Companies Inc. is scheduled for Tuesday, April 28th, with a consensus estimate EPS of 0.694.
BHC's current price stands at $5.72, reflecting a 2.6% increase from the previous close. With a trading volume of $467,261, BHC has seen a price change of 14.5 cents.
In the latest quarterly earnings report on Tuesday, February 17th, BHC reported a consensus estimate EPS of 1.21. The company's revenue and profit margin figures were not provided in the data.
BHC's cash flow indicates positive operating cash flow of $495.92 million and free cash flow of $402.53 million. Notably, the net change in cash is -$16.11 million.
BHC reported a revenue of $2.84 billion with a gross profit of $1.79 billion. Operating income stands at $730 million, while the company recorded a net loss of $113.72 million.
Key ratios for BHC show a quick ratio of 1.08, gross profit margin of 63%, and a return on equity of 20.56%. Notably, the net profit margin is -4.01%.
BHC's balance sheet highlights total assets of $26.32 billion, total liabilities of $25.94 billion, and net debt of $19.88 billion, reflecting the company's financial position.
This report provides insights into BHC's financial performance, upcoming earnings, and key financial metrics, positioning the asset for continued market attention.
Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.